Fundraising Fox
/Companies
Sign in

Confluence Pharmaceuticals

Carmel, US · 3 known investors

Find your way into Confluence Pharmaceuticals

Sign up to see every warm intro you have to Confluence Pharmaceuticals

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Confluence Pharmaceuticals team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Confluence Pharma is a clinical-stage biopharmaceutical company developing sustained-release drug formulations to treat the core social and communication impairments of Fragile X Syndrome, Autism, and other neurodevelopmental, neuropsychiatric, and addiction-related disorders. Its treatments target pediatric and adult patients, addressing symptoms such as communication, social behavior, attention, anxiety, and hyperactivity.

BiotechDigital Health

Founders & leadership

SLSteven L. Johns
Steven L. JohnsPresident & Founder

Board

BWBoyd W. Sturdevant, Jr.
Boyd W. Sturdevant, Jr.Chairman & Founder

Investors · 3

IU Ventureslisted by IU VenturesBloomington

How we know: funding news · iuventures.com · Not right? Tell us

Also in the syndicate · 1

IU Philanthropic Venture Fund

Funding

SEC filings, press & company announcements

$1.3M disclosed across 2 of 4 rounds · 2016–2022

▶$10KraisedOct 2018 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Phil LodatoDirector
  • Steven L. JohnsExecutive Officer, Director
  • Boyd W. Sturdevant, Jr.Director
Offering amount
$800K
Amount sold
$10K
Minimum investment
$10K
First sale
Sep 2018
Incorporated
Limited Liability Company, Indiana
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.3MraisedNov 2016 · 10 investors · Pharmaceuticals
Rule 506(c)
Officers, directors & promoters on the filing
  • Boyd W. Sturdevant, Jr.Director
  • Steven L. JohnsExecutive Officer, Director
Offering amount
$1.3M
Amount sold
$1.3M
Minimum investment
$25K
First sale
Apr 2016
Incorporated
Limited Liability Company, Indiana
Federal exemptions
06c
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 5

Confluence TechnologiesConfluence provides data aggregation, analytics, and reporting solutions for investment consultants to analyze funds and deliver performance and risk insights to their clients.
Aclaris TherapeuticsAclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases. The company's clinical and preclinical pipeline includes candidates in development for severe asthma, atopic dermatitis, and T-cell-mediated autoimmune conditions.
AtlassianAtlassian offers a teamwork platform combining project planning, knowledge management, and AI orchestration tools for teams and their AI agents. Its products help organizations plan, execute, and deliver work at scale.
CircumventCircumvent develops precision medicines for neurodegenerative diseases, with current focus on Batten Disease and other rare neurological disorders. The company's research targets synaptic dysfunction and lysosomal pathways through investigation of the palmitoylome.
Collegium PharmaceuticalCollegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions. It serves patients living with serious medical conditions and the healthcare professionals caring for them.

Companies working in the same space as Confluence Pharmaceuticals.

Frequently asked questions

What does Confluence Pharmaceuticals do?
Confluence Pharma is a clinical-stage biopharmaceutical company developing sustained-release drug formulations to treat the core social and communication impairments of Fragile X Syndrome, Autism, and other neurodevelopmental, neuropsychiatric, and addiction-related disorders. Its treatments target pediatric and adult patients, addressing symptoms such as communication, social behavior, attention, anxiety, and hyperactivity.
Who are Confluence Pharmaceuticals's investors?
Confluence Pharmaceuticals's investors include Elevate Ventures, IU Ventures.
How much funding has Confluence Pharmaceuticals raised?
Confluence Pharmaceuticals has disclosed $1.3M raised across 2 of its 4 known rounds.
Where is Confluence Pharmaceuticals headquartered?
Confluence Pharmaceuticals is headquartered in Carmel, US.